Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Leases: 2019-2021

Historic Capital Leases for Fulcrum Therapeutics (FULC) over the last 3 years, with Dec 2021 value amounting to $2.6 million.

  • Fulcrum Therapeutics' Capital Leases fell 15.37% to $2.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $2.6 million, marking a year-over-year decrease of 15.37%. This contributed to the annual value of $2.6 million for FY2021, which is 15.37% down from last year.
  • According to the latest figures from Q4 2021, Fulcrum Therapeutics' Capital Leases is $2.6 million, which was down 4.33% from $2.7 million recorded in Q3 2021.
  • Over the past 5 years, Fulcrum Therapeutics' Capital Leases peaked at $3.8 million during Q2 2019, and registered a low of $2.6 million during Q4 2021.
  • In the last 3 years, Fulcrum Therapeutics' Capital Leases had a median value of $3.2 million in 2020 and averaged $3.2 million.
  • Data for Fulcrum Therapeutics' Capital Leases shows a maximum YoY dropped of 15.37% (in 2021) over the last 5 years.
  • Quarterly analysis of 3 years shows Fulcrum Therapeutics' Capital Leases stood at $3.5 million in 2019, then decreased by 13.35% to $3.1 million in 2020, then dropped by 15.37% to $2.6 million in 2021.
  • Its Capital Leases stands at $2.6 million for Q4 2021, versus $2.7 million for Q3 2021 and $2.8 million for Q2 2021.